Evaluation of molecular prognostic and predictive factors: An important step towards personalised treatment in non small cell lung cancer

Alfredo Tartarone; Rose Lerose; Giuseppina Gallucci; Raffaele Ardito; Michele Aieta

doi:10.1007/s12032-011-9992-y

Evaluation of molecular prognostic and predictive factors: An important step towards personalised treatment in non small cell lung cancer

Alfredo Tartarone, Rose Lerose, Giuseppina Gallucci, Raffaele Ardito, Michele Aieta

IRCCS Centro di Riferimento Oncologico della Basilicata (CROB)

Research output: Contribution to journal › Article › peer-review

Abstract

Treatment for patients with advanced NSCLC generally consists of chemotherapy, but response rates are modest and recurrence occurs for most patients after standard first-line platinum-based doublet therapy. Tailoring therapy to individual patient according to certain prognostic and predictive factors has the potential to improve outcome in NSCLC. This review focuses on the most important molecular prognostic and/or predictive factors in the treatment of advanced NSCLC; considering these molecular features, we also suggest a molecularbased treatment algorithm.

Original language	English
Pages (from-to)	1599-1605
Number of pages	7
Journal	Medical Oncology
Volume	29
Issue number	3
DOIs	https://doi.org/10.1007/s12032-011-9992-y
Publication status	Published - Sep 2012

Keywords

ALK fusion oncogenes
Breast cancer susceptibility gene 1
Epidermal growth factor receptor
Excision repair cross-complementation 1
Molecular-based treatment algorithm
Non small cell lung cancer
Ribonucleotide reductase M1
Thymidylate synthase

ASJC Scopus subject areas

Oncology
Cancer Research
Hematology

Access to Document

10.1007/s12032-011-9992-y

Cite this

@article{6d529efc5d9440d29b70bc14cb8e092c,

title = "Evaluation of molecular prognostic and predictive factors: An important step towards personalised treatment in non small cell lung cancer",

abstract = "Treatment for patients with advanced NSCLC generally consists of chemotherapy, but response rates are modest and recurrence occurs for most patients after standard first-line platinum-based doublet therapy. Tailoring therapy to individual patient according to certain prognostic and predictive factors has the potential to improve outcome in NSCLC. This review focuses on the most important molecular prognostic and/or predictive factors in the treatment of advanced NSCLC; considering these molecular features, we also suggest a molecularbased treatment algorithm.",

keywords = "ALK fusion oncogenes, Breast cancer susceptibility gene 1, Epidermal growth factor receptor, Excision repair cross-complementation 1, Molecular-based treatment algorithm, Non small cell lung cancer, Ribonucleotide reductase M1, Thymidylate synthase",

author = "Alfredo Tartarone and Rose Lerose and Giuseppina Gallucci and Raffaele Ardito and Michele Aieta",

year = "2012",

month = sep,

doi = "10.1007/s12032-011-9992-y",

language = "English",

volume = "29",

pages = "1599--1605",

journal = "Medical Oncology",

issn = "1357-0560",

publisher = "Humana Press Inc.",

number = "3",

}

TY - JOUR

T1 - Evaluation of molecular prognostic and predictive factors

T2 - An important step towards personalised treatment in non small cell lung cancer

AU - Tartarone, Alfredo

AU - Lerose, Rose

AU - Gallucci, Giuseppina

AU - Ardito, Raffaele

AU - Aieta, Michele

PY - 2012/9

Y1 - 2012/9

N2 - Treatment for patients with advanced NSCLC generally consists of chemotherapy, but response rates are modest and recurrence occurs for most patients after standard first-line platinum-based doublet therapy. Tailoring therapy to individual patient according to certain prognostic and predictive factors has the potential to improve outcome in NSCLC. This review focuses on the most important molecular prognostic and/or predictive factors in the treatment of advanced NSCLC; considering these molecular features, we also suggest a molecularbased treatment algorithm.

AB - Treatment for patients with advanced NSCLC generally consists of chemotherapy, but response rates are modest and recurrence occurs for most patients after standard first-line platinum-based doublet therapy. Tailoring therapy to individual patient according to certain prognostic and predictive factors has the potential to improve outcome in NSCLC. This review focuses on the most important molecular prognostic and/or predictive factors in the treatment of advanced NSCLC; considering these molecular features, we also suggest a molecularbased treatment algorithm.

KW - ALK fusion oncogenes

KW - Breast cancer susceptibility gene 1

KW - Epidermal growth factor receptor

KW - Excision repair cross-complementation 1

KW - Molecular-based treatment algorithm

KW - Non small cell lung cancer

KW - Ribonucleotide reductase M1

KW - Thymidylate synthase

UR - http://www.scopus.com/inward/record.url?scp=84872782325&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872782325&partnerID=8YFLogxK

U2 - 10.1007/s12032-011-9992-y

DO - 10.1007/s12032-011-9992-y

M3 - Article

C2 - 21633836

AN - SCOPUS:84872782325

VL - 29

SP - 1599

EP - 1605

JO - Medical Oncology

JF - Medical Oncology

SN - 1357-0560

IS - 3

ER -

Evaluation of molecular prognostic and predictive factors: An important step towards personalised treatment in non small cell lung cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this